TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06873854: Evaluation of a Phase II, Single-arm, Multicenter, Open-label Clinical Study on LM-108 Injection in Combination With Toripalimab for Advanced Malignant Solid Tumors in Patients With Unresectable or Metastatic Microsatell

Sponsor: LaNova Medicines Limited · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06873854 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06873854 Rescue Dossier →